PF 6273340

Drug Profile

PF 6273340

Alternative Names: PF-06273340; PF-6273340

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator Pfizer
  • Class Analgesics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 06 Oct 2014 Pfizer plans a phase I trial in Pain (In volunteers) in the Netherlands (NCT02260947)
  • 07 Aug 2014 Discontinued - Phase-I for Pain (In volunteers) in Belgium (PO)
  • 07 Aug 2014 Discontinued - Phase-I for Pain (In volunteers) in Singapore (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top